The FDA and CDC have given a thumbs-up for third booster doses of mRNA vaccines in immunocompromised individuals, but this won't translate to a lot of extra revenue for Pfizer or Moderna.
There's a relatively small market in the U.S. for booster doses under the current EUAs.
The U.S. government has also already secured supply deals for more than enough doses to fully vaccinate every American and give a third booster dose.
